Evidence map›Paper›PMID 28622387›Full record

ArticlePloS one2017

Estimates and impact of lymphocyte division parameters from CFSE data using mathematical modelling.

Pauline Mazzocco, Samuel Bernard, Laurent Pujo-Menjouet

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Pauline MazzoccoUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France.
Samuel BernardUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut Camille Jordan, Villeurbanne, France.
Laurent Pujo-MenjouetUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut Camille Jordan, Villeurbanne, France.
Université Claude Bernard Lyon 1 · FRCentre Inria de l'Université Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carboxyfluorescein diacetate succinimidyl ester (CFSE) labelling has been widely used to track and study cell proliferation. Here we use mathematical modelling to describe the kinetics of immune cell proliferation after an in vitro polyclonal stimulation tracked with CFSE. This approach allows us to estimate a set of key parameters, including ones related to cell death and proliferation. We develop a three-phase model that distinguishes a latency phase, accounting for non-divided cell behaviour, a resting phase and the active phase of the division process. Parameter estimates are derived from model results, and numerical simulations are then compared to the dynamics of in vitro experiments, with different biological assumptions tested. Our model allows us to compare the dynamics of CD4+ and CD8+ cells, and to highlight their kinetic differences. Finally we perform a sensitivity analysis to quantify the impact of each parameter on proliferation kinetics. Interestingly, we find that parameter sensitivity varies with time and with cell generation. Our approach can help biologists to understand cell proliferation mechanisms and to identify potential pathological division processes.

Indexed as

Models, BiologicalCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DivisionFluoresceinsFluorescent DyesHumansStaining and LabelingSuccinimides5-(6)-carboxyfluorescein diacetate succinimidyl esterFluoresceinsFluorescent DyesSuccinimides

Identifiers

PMID28622387
PMCPMC5473582
OpenAlexW2626808986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.